FLT3 antibody

Catalog No. ABIN2422676

Product Details anti-FLT3 Antibody

Target: FLT3 (Fms-Related tyrosine Kinase 3 (FLT3))

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This FLT3 antibody is un-conjugated

Application: ELISA, Immunohistochemistry (IHC)

Purification: Affinity purification

Immunogen: Recombinant protein of human FLT3

Isotype: IgG

Application Details

Application Notes: IHC 1:50-1:200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4

Preservative: Sodium azide

Handling Advice: Avoid freeze / thaw cycles.

Storage: -20 °C

Storage Comment: Store at -20°C. Avoid freeze / thaw cycles.

Target Details for FLT3

Target: FLT3 (Fms-Related tyrosine Kinase 3 (FLT3))

Alternative Name: FLT3 (FLT3 Products)

Synonyms: FLT3 antibody, B230315G04 antibody, CD135 antibody, Flk-2 antibody, Flk2 antibody, Flt-3 antibody, Ly72 antibody, wmfl antibody, FLK-2 antibody, FLK2 antibody, STK1 antibody, fms related tyrosine kinase 3 antibody, FMS-like tyrosine kinase 3 antibody, fms-related tyrosine kinase 3 antibody, FLT3 antibody, Flt3 antibody

Background: This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.

Pathways: RTK Signaling